Oncology Nursing Forum:急性淋巴细胞白血病患儿及其母亲睡眠质量堪忧

2014-12-22 BIOON 生物谷

近日,Ellyn Matthews博士发表了关于白血病">急性淋巴细胞白血病(ALL)儿童和他们母亲的睡眠的研究成果。 这项题目名为“Sleep in Mother and Child Dyads During Treatment for Pediatric Acute Lymphoblastic Leukemia”的研究发表在杂志Oncology Nursing Forum上。 研究作

近日,Ellyn Matthews博士发表了关于白血病">急性淋巴细胞白血病(ALL)儿童和他们母亲的睡眠的研究成果。

这项题目名为“Sleep in Mother and Child Dyads During Treatment for Pediatric Acute Lymphoblastic Leukemia”的研究发表在杂志Oncology Nursing Forum上。

研究作者指出,在刚出生到14岁之间,儿童癌症形式中,ALL占到癌症诊断的三分之一,虽然相比其他类型的癌症,ALL的存活率有一定的优势,但ALL症状如睡眠中断和疲劳会给儿童以及家庭或护理者带来很大困扰。

为了更好地了解这些情况,研究人员让研究对象完成问卷调查和睡眠日记,以评估他们的睡眠时间数量和质量。此外,ALL儿童母亲和戴上腕表,以检测他们的运动和睡眠/休息、觉醒周期。

与对照组相比,ALL儿童与他们的母亲报道有更严重的失眠,更严重的失眠与焦虑,抑郁症状等有关。研究发现ALL孩子都需要较长的时间才能入睡,有更糟糕的睡眠习惯和模式。

原始出处

Matthews EE1, Neu M1, Cook PF1, King N2.Sleep in mother and child dyads during treatment for pediatric acute lymphoblastic leukemia.Oncol Nurs Forum. 2014 Nov 1

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=69446, encodeId=15e669446ef, content=很新颖, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c131700148, createdName=1de7c58bm26(暂无匿称), createdTime=Mon Mar 14 20:13:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864577, encodeId=c64d18645e7dc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Sep 21 06:17:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997801, encodeId=6c2e199e8013f, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Oct 27 12:17:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674346, encodeId=349b16e4346ed, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Thu Oct 22 01:17:00 CST 2015, time=2015-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13755, encodeId=19cd13e5568, content=值得思考和借鉴!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=WUYUN, createdTime=Mon Jan 05 15:20:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302000, encodeId=066c130200049, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305721, encodeId=6f331305e218b, content=<a href='/topic/show?id=e87de303850' target=_blank style='color:#2F92EE;'>#睡眠质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73038, encryptionId=e87de303850, topicName=睡眠质量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13338, encodeId=ea7a1333873, content=能给人启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=919e1609078, createdName=duoduolo, createdTime=Mon Dec 22 20:45:00 CST 2014, time=2014-12-22, status=1, ipAttribution=)]
    2016-03-14 1de7c58bm26(暂无匿称)

    很新颖

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=69446, encodeId=15e669446ef, content=很新颖, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c131700148, createdName=1de7c58bm26(暂无匿称), createdTime=Mon Mar 14 20:13:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864577, encodeId=c64d18645e7dc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Sep 21 06:17:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997801, encodeId=6c2e199e8013f, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Oct 27 12:17:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674346, encodeId=349b16e4346ed, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Thu Oct 22 01:17:00 CST 2015, time=2015-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13755, encodeId=19cd13e5568, content=值得思考和借鉴!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=WUYUN, createdTime=Mon Jan 05 15:20:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302000, encodeId=066c130200049, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305721, encodeId=6f331305e218b, content=<a href='/topic/show?id=e87de303850' target=_blank style='color:#2F92EE;'>#睡眠质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73038, encryptionId=e87de303850, topicName=睡眠质量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13338, encodeId=ea7a1333873, content=能给人启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=919e1609078, createdName=duoduolo, createdTime=Mon Dec 22 20:45:00 CST 2014, time=2014-12-22, status=1, ipAttribution=)]
    2015-09-21 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=69446, encodeId=15e669446ef, content=很新颖, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c131700148, createdName=1de7c58bm26(暂无匿称), createdTime=Mon Mar 14 20:13:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864577, encodeId=c64d18645e7dc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Sep 21 06:17:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997801, encodeId=6c2e199e8013f, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Oct 27 12:17:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674346, encodeId=349b16e4346ed, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Thu Oct 22 01:17:00 CST 2015, time=2015-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13755, encodeId=19cd13e5568, content=值得思考和借鉴!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=WUYUN, createdTime=Mon Jan 05 15:20:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302000, encodeId=066c130200049, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305721, encodeId=6f331305e218b, content=<a href='/topic/show?id=e87de303850' target=_blank style='color:#2F92EE;'>#睡眠质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73038, encryptionId=e87de303850, topicName=睡眠质量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13338, encodeId=ea7a1333873, content=能给人启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=919e1609078, createdName=duoduolo, createdTime=Mon Dec 22 20:45:00 CST 2014, time=2014-12-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=69446, encodeId=15e669446ef, content=很新颖, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c131700148, createdName=1de7c58bm26(暂无匿称), createdTime=Mon Mar 14 20:13:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864577, encodeId=c64d18645e7dc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Sep 21 06:17:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997801, encodeId=6c2e199e8013f, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Oct 27 12:17:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674346, encodeId=349b16e4346ed, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Thu Oct 22 01:17:00 CST 2015, time=2015-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13755, encodeId=19cd13e5568, content=值得思考和借鉴!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=WUYUN, createdTime=Mon Jan 05 15:20:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302000, encodeId=066c130200049, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305721, encodeId=6f331305e218b, content=<a href='/topic/show?id=e87de303850' target=_blank style='color:#2F92EE;'>#睡眠质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73038, encryptionId=e87de303850, topicName=睡眠质量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13338, encodeId=ea7a1333873, content=能给人启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=919e1609078, createdName=duoduolo, createdTime=Mon Dec 22 20:45:00 CST 2014, time=2014-12-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=69446, encodeId=15e669446ef, content=很新颖, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c131700148, createdName=1de7c58bm26(暂无匿称), createdTime=Mon Mar 14 20:13:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864577, encodeId=c64d18645e7dc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Sep 21 06:17:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997801, encodeId=6c2e199e8013f, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Oct 27 12:17:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674346, encodeId=349b16e4346ed, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Thu Oct 22 01:17:00 CST 2015, time=2015-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13755, encodeId=19cd13e5568, content=值得思考和借鉴!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=WUYUN, createdTime=Mon Jan 05 15:20:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302000, encodeId=066c130200049, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305721, encodeId=6f331305e218b, content=<a href='/topic/show?id=e87de303850' target=_blank style='color:#2F92EE;'>#睡眠质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73038, encryptionId=e87de303850, topicName=睡眠质量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13338, encodeId=ea7a1333873, content=能给人启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=919e1609078, createdName=duoduolo, createdTime=Mon Dec 22 20:45:00 CST 2014, time=2014-12-22, status=1, ipAttribution=)]
    2015-01-05 WUYUN

    值得思考和借鉴!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=69446, encodeId=15e669446ef, content=很新颖, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c131700148, createdName=1de7c58bm26(暂无匿称), createdTime=Mon Mar 14 20:13:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864577, encodeId=c64d18645e7dc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Sep 21 06:17:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997801, encodeId=6c2e199e8013f, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Oct 27 12:17:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674346, encodeId=349b16e4346ed, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Thu Oct 22 01:17:00 CST 2015, time=2015-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13755, encodeId=19cd13e5568, content=值得思考和借鉴!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=WUYUN, createdTime=Mon Jan 05 15:20:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302000, encodeId=066c130200049, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305721, encodeId=6f331305e218b, content=<a href='/topic/show?id=e87de303850' target=_blank style='color:#2F92EE;'>#睡眠质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73038, encryptionId=e87de303850, topicName=睡眠质量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13338, encodeId=ea7a1333873, content=能给人启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=919e1609078, createdName=duoduolo, createdTime=Mon Dec 22 20:45:00 CST 2014, time=2014-12-22, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=69446, encodeId=15e669446ef, content=很新颖, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c131700148, createdName=1de7c58bm26(暂无匿称), createdTime=Mon Mar 14 20:13:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864577, encodeId=c64d18645e7dc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Sep 21 06:17:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997801, encodeId=6c2e199e8013f, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Oct 27 12:17:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674346, encodeId=349b16e4346ed, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Thu Oct 22 01:17:00 CST 2015, time=2015-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13755, encodeId=19cd13e5568, content=值得思考和借鉴!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=WUYUN, createdTime=Mon Jan 05 15:20:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302000, encodeId=066c130200049, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305721, encodeId=6f331305e218b, content=<a href='/topic/show?id=e87de303850' target=_blank style='color:#2F92EE;'>#睡眠质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73038, encryptionId=e87de303850, topicName=睡眠质量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13338, encodeId=ea7a1333873, content=能给人启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=919e1609078, createdName=duoduolo, createdTime=Mon Dec 22 20:45:00 CST 2014, time=2014-12-22, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=69446, encodeId=15e669446ef, content=很新颖, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c131700148, createdName=1de7c58bm26(暂无匿称), createdTime=Mon Mar 14 20:13:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864577, encodeId=c64d18645e7dc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Sep 21 06:17:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997801, encodeId=6c2e199e8013f, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Oct 27 12:17:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674346, encodeId=349b16e4346ed, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Thu Oct 22 01:17:00 CST 2015, time=2015-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13755, encodeId=19cd13e5568, content=值得思考和借鉴!, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=WUYUN, createdTime=Mon Jan 05 15:20:00 CST 2015, time=2015-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302000, encodeId=066c130200049, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305721, encodeId=6f331305e218b, content=<a href='/topic/show?id=e87de303850' target=_blank style='color:#2F92EE;'>#睡眠质量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73038, encryptionId=e87de303850, topicName=睡眠质量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=13338, encodeId=ea7a1333873, content=能给人启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=919e1609078, createdName=duoduolo, createdTime=Mon Dec 22 20:45:00 CST 2014, time=2014-12-22, status=1, ipAttribution=)]
    2014-12-22 duoduolo

    能给人启发

    0

相关威廉亚洲官网

ASH 2014:HSCT后单纯性持续性血小板减少症机制

异基因造血干细胞移植是根治恶性血液病等严重危害人类健康的疾病的重要手段。单纯性持续性血小板减少症是移植后影响患者长期生存的重要的合并症。其发病机制多年来一直未有突破性进展。本课题组系列的原创性的研究工作得到了美国血液学会(ASH)年会专家的邀请,并在本次年会做大会口头报告。 北京大学血液病研究所在2014年ASH年会上共有3个口头报告,是北京大学血液病研究所数量最多的一次。 ——北京大学人民医

ASH 2014:osaroxin+阿糖胞苷改善复发性AML患者的生存

Vosaroxin+阿糖胞苷(Ara-C)对比安慰剂+Ara-C改善了复发/难治急性髓性白血病">白血病(AML)患者的生存 :Ⅲ期双盲随机对照多中心研究(VALOR研究) 北京大学人民医院、北京大学血液病研究所 江浩 难治/复发AML的治疗40年来无重大突破,此届ASH公布了新型制剂vosaroxin联合Ara-C的研究数据,以更多的病例数据证实了可提高此群患者的疗效和生存,尤其在老年

ASH 2014:中高危MDS和CMML的临床难题仍待探索

北京协和医院血液科庄俊玲副教授应记者邀请对当地时间12月9日上午ASH2014公布的一项关于中高危骨髓异常增生综合征(MDS)和慢性粒单核细胞白血病">白血病(CMML)的最新揭晓临床研究(LBA)给予了解读。 Sekeres M.A.等代表北美协作组多家单位,将SWOG S1117方案的初步结果(摘要号:LBA-5)在今年ASH会议上汇报。这项Ⅱ期随机临床试验比较了去甲基化药物阿扎胞

ASH 2014:Imbruvica使携带del17p突变的CLL患者获益

2014年第56届美国血液学会年会(ASH)于12月6日-9日在美国旧金山举行。会上公布了抗癌药Imbruvica(ibrutinib)II期RESONATE-17(PCYC-1117)研究的数据。研究中,144例携带del17p突变的复发性/难治性慢性淋巴细胞白血病">白血病(CLL,n=133)患者和小细胞淋巴瘤(SLL,n=7)患者接受每日一次Imbruvica单药治疗,直至病情进展。

ASH 2014:癌症治疗价格日益攀升的伦理问题

不要迁怒于信使 在美国,约20%的国内生产总值被用于医疗卫生领域,其中5%用于癌症治疗。随着越来越多的人被诊断为癌症,进入市场的化疗药物数量呈现指数型增加,化疗费用也是如此。2012年,美国食品药品监督局批准了三种治疗慢性骨髓性白血病">白血病(CML)的新药物,这三种药物的每年费用达一百万美元,将近是2001年伊马替尼(格列卫)的5倍。被转嫁给患者的部分费用日益增加,导致严重的“经济毒性

ASH 2014:儿童ALL的基因组分析研究

过去半个世纪医学界最伟大的成就之一是儿童急性淋巴细胞性白血病">白血病(ALL)治疗实现了将近90%的无事件生存率。虽然取得了这样的成绩,ALL依然是儿童癌症相关死亡的主要致病因。在williamhill asia 致力研究进一步提高ALL和其它癌症治疗的进程中,癌症基因学的前沿领域为williamhill asia 提供了巨大潜力。本次教育项目会议“洞察儿童恶性血液病:以急性淋巴细胞性白血病为重点”将提供有关儿童ALL的最新讯息,讨论该领域的最新进